APA (7th ed.) Citation

Schuster, A., Caimmi, D., Nolte, H., Novakova, S., Mikler, J., Foss-Skiftesvik, M. H., . . . Pfaar, O. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): A randomised, double-blind, placebo-controlled, phase III trialResearch in context. Elsevier.

Chicago Style (17th ed.) Citation

Schuster, Antje, et al. Efficacy and Safety of SQ House Dust Mite Sublingual Immunotherapy-tablet (12 SQ-HDM) in Children with Allergic Rhinitis/rhinoconjunctivitis with or Without Asthma (MT-12): A Randomised, Double-blind, Placebo-controlled, Phase III TrialResearch in Context. Elsevier.

MLA (9th ed.) Citation

Schuster, Antje, et al. Efficacy and Safety of SQ House Dust Mite Sublingual Immunotherapy-tablet (12 SQ-HDM) in Children with Allergic Rhinitis/rhinoconjunctivitis with or Without Asthma (MT-12): A Randomised, Double-blind, Placebo-controlled, Phase III TrialResearch in Context. Elsevier.